Variables that can lead to a dysfunction or act as antagonists of GIP have been shown to reduce obesity and insulin resistance [12]. Daily administration of GIP antagonists, such as (Pro3)GIP, has been able to promote weight loss and ameliorate insulin resistance in mice [11,13]. Obese patients subjected to bariatric surgery, that involves bypass of part of the small intestine, and consequently reduction of GIP secretion, presented restoration of normal glucose tolerance prior to weight loss [14].
